Lygos Stock
Biotechnology solutions
About Lygos Stock
Founded in 2010, Lygos is providing biotechnology solutions for today’s renewable chemical challenges. They engineer microbes to convert sugars into high-value, industrial chemicals, targeting compounds where biological production is cost-advantaged over petrochemical production.
Investors
First Round Capital
Flexport, AppNexus, Blue Apron, Clover Health, Fab, Earnest, Warby Parker, LendingHome, Boxed, Looker
LG Technology Ventures
National Science Foundation
US Department of Energy
Y Combinator
Airbnb, DoorDash, Instacart, Flexport, Rappi, Stripe, Ginkgo Bioworks, Coinbase, Machine Zone, Zenefits
Funding History
| April 2012 | $150K |
|---|---|
| April 2013 | $1.0M |
| December 2014 | $550K |
| December 2016 | $13.0M |
| July 2018 | $15.5M |
| September 2018 | $2.0M |
| January 2019 | $10.0M |
| March 2019 | $750K |
| June 2019 | $2.0M |
Management
Founder & Chief Executive Officer
Eric Steen
Chief Patent Counsel
Photon Rao
Press
Business Wire - Sep, 5 2019
Business Wire - Aug, 7 2019
Business Wire - Jun, 3 2019
AP - May, 7 2019
Synbiobeta - Apr, 12 2019
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Lygos or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
